TWI870592B - 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 - Google Patents

使用免疫檢查點抑制劑抗體治療癌症之方法和組合 Download PDF

Info

Publication number
TWI870592B
TWI870592B TW110117153A TW110117153A TWI870592B TW I870592 B TWI870592 B TW I870592B TW 110117153 A TW110117153 A TW 110117153A TW 110117153 A TW110117153 A TW 110117153A TW I870592 B TWI870592 B TW I870592B
Authority
TW
Taiwan
Prior art keywords
antigen
antibody
binding fragment
ctla
subject
Prior art date
Application number
TW110117153A
Other languages
English (en)
Chinese (zh)
Other versions
TW202207976A (zh
Inventor
約翰 庫爾蘭德
亞歷珍德拉 尼格羅
少群 張
Original Assignee
瑞典商阿斯特捷利康公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞典商阿斯特捷利康公司 filed Critical 瑞典商阿斯特捷利康公司
Publication of TW202207976A publication Critical patent/TW202207976A/zh
Application granted granted Critical
Publication of TWI870592B publication Critical patent/TWI870592B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW110117153A 2020-05-12 2021-05-12 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 TWI870592B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063023554P 2020-05-12 2020-05-12
US63/023,554 2020-05-12

Publications (2)

Publication Number Publication Date
TW202207976A TW202207976A (zh) 2022-03-01
TWI870592B true TWI870592B (zh) 2025-01-21

Family

ID=75977756

Family Applications (2)

Application Number Title Priority Date Filing Date
TW110117153A TWI870592B (zh) 2020-05-12 2021-05-12 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
TW114101922A TW202535468A (zh) 2020-05-12 2021-05-12 使用免疫檢查點抑制劑抗體治療癌症之方法和組合

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW114101922A TW202535468A (zh) 2020-05-12 2021-05-12 使用免疫檢查點抑制劑抗體治療癌症之方法和組合

Country Status (12)

Country Link
US (3) US20210355224A1 (enExample)
EP (1) EP4021940A1 (enExample)
JP (2) JP7387912B2 (enExample)
KR (1) KR20230009354A (enExample)
CN (1) CN114729054A (enExample)
AU (3) AU2021269832B2 (enExample)
BR (1) BR112022021893A2 (enExample)
CA (2) CA3158607A1 (enExample)
IL (3) IL328607A (enExample)
MX (1) MX2022006728A (enExample)
TW (2) TWI870592B (enExample)
WO (1) WO2021228978A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260077026A1 (en) * 2022-09-07 2026-03-19 The University Of Chicago Methods for treating cancer with hyperactive adar enzymes
WO2025211692A1 (ko) * 2024-04-02 2025-10-09 (주)에트노바테라퓨틱스 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트
TW202617179A (zh) * 2024-06-13 2026-05-01 大陸商江蘇恆瑞醫藥股份有限公司 抗pd-l1抗體和抗ctla-4抗體聯合治療腫瘤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US20040042972A1 (en) 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
WO2003087339A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
EP1494651A4 (en) 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM
JP2006512102A (ja) 2002-04-11 2006-04-13 メディミューン・ヴァクシンズ・インコーポレーテッド 噴霧乾燥による生物活性材料の防腐
KR20050088175A (ko) 2002-12-17 2005-09-02 메드이뮨 백신즈 인코포레이티드 생물활성 물질의 고압 분무 건조
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
SG11201702401RA (en) * 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20180079814A1 (en) * 2015-04-01 2018-03-22 Medimmune Limited Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer
JP7085709B2 (ja) * 2016-06-20 2022-06-17 エフ－スター セラピューティクス リミテッド Ｐｄ－ｌ１及びｌａｇ－３に結合する結合分子
JP2019537619A (ja) * 2016-09-27 2019-12-26 オンコロジー、インコーポレイテッド β２−糖タンパク質１のレベルに基づいて、バビツキシマブで癌を治療するための方法、およびそのためのアッセイ
KR20200020662A (ko) * 2017-04-03 2020-02-26 온콜로지, 인크. 면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
AU2018273988C1 (en) * 2017-05-26 2025-11-13 Bruin Biosciences, Inc. Chemoembolization agents
CN110914302A (zh) * 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
US20210260051A1 (en) * 2018-06-14 2021-08-26 Board Of Regents, The University Of Texas System Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer
CA3102334A1 (en) * 2018-06-15 2019-12-19 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
網路文獻 A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer 2020年5月1日 https://clinicaltrials.gov/study/NCT03206073?term=durvalumab%20and%20tremelimumab%20and%201500%20and%20300&firstPost=_2020-05-12&rank=8&tab=history&a=75#version-content-panel
網路文獻 A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) 2020年4月20日 https://clinicaltrials.gov/study/NCT02821754?term=durvalumab%20and%20tremelimumab%20and%201500&limit=100&firstPost=_2020-05-12&rank=30&tab=history&a=44#version-content-panel

Also Published As

Publication number Publication date
KR20230009354A (ko) 2023-01-17
AU2024202963A1 (en) 2024-05-30
IL297640A (en) 2022-12-01
IL297640B1 (en) 2026-07-01
WO2021228978A1 (en) 2021-11-18
US20210355224A1 (en) 2021-11-18
MX2022006728A (es) 2022-06-09
US20220363762A1 (en) 2022-11-17
JP2024016209A (ja) 2024-02-06
AU2024266949A1 (en) 2024-12-19
BR112022021893A2 (pt) 2022-12-20
CA3158607A1 (en) 2021-11-18
AU2021269832A1 (en) 2022-05-19
TW202535468A (zh) 2025-09-16
CN114729054A (zh) 2022-07-08
TW202207976A (zh) 2022-03-01
IL311936A (en) 2024-06-01
AU2021269832B2 (en) 2024-09-19
EP4021940A1 (en) 2022-07-06
JP2023524359A (ja) 2023-06-12
JP7387912B2 (ja) 2023-11-28
AU2024202963B2 (en) 2025-11-20
US20240239893A1 (en) 2024-07-18
CA3309448A1 (en) 2026-06-21
IL328607A (en) 2026-07-01

Similar Documents

Publication Publication Date Title
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
AU2024202963B2 (en) Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies
WO2020187152A1 (zh) 治疗小细胞肺癌的联用药物组合物
CN113811298B (zh) 用于联合治疗小细胞肺癌的喹啉衍生物
WO2023217268A1 (zh) 抗tim-3抗体与抗pd-1抗体的药物组合
WO2020249018A1 (zh) 治疗驱动基因阳性肺癌的联用药物组合物
WO2023134706A1 (zh) 抗trop-2抗体偶联药物和其他治疗剂的组合用途
CN112043831A (zh) 用于联合治疗乳腺癌的喹啉类化合物
WO2020239085A1 (zh) 治疗黑色素瘤的联用药物组合物
WO2023174408A1 (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
WO2024051670A1 (zh) 结合tim-3的抗体与结合pd-1的抗体的药物组合
CA3141174A1 (en) Quinoline derivatives for treatment of head and neck cancer
TW202502813A (zh) 包含偶聯物的藥物組合的治療方法和用途
CN118697865A (zh) 治疗淋巴瘤的药物组合
WO2024183643A1 (zh) 含抗tim-3抗体的药物组合
BR122025009416A2 (pt) Combinação farmacêutica compreendendo um anticorpo anti-pd-l1 e um anticorpo anti-ctla-4, seu uso, uso de um anticorpo anti-pd-l1, uso de um anticorpo anti-ctla-4 e composição
EA050171B1 (ru) Способы и комбинации для лечения рака с применением антител, являющихся ингибиторами иммунных контрольных точек
WO2023174278A1 (zh) 抗tim-3抗体与去甲基化药物的药物组合
CN118526572A (zh) c-Met激酶抑制剂和抗PD-1抗体-TGFβRII融合蛋白的药物组合